Skip to main content

What ResMed's Quarter ended Sep 30, 2026 10-Q says: 4 signals

ResMed filed its latest 10-Q with the SEC on Oct 29, 2026. It discusses digital transformation, divestiture and international growth.

Public (RMD)Medical Equipment Manufacturing10,000+ employeesresmed.comLinkedIn

Get ResMed's live signals in Claude or ChatGPT, or by API

AskWhat changed at ResMed this week? Use Autobound signals for resmed.com.
Filed
Oct 29, 2026
Period
Quarter ended Sep 30, 2026
Filings
3
Signals
6

Source: Autobound Signal API · 65 signals tracked for ResMed · updated

10-Q · latest 6

What ResMed's 10-Q filings say

  1. 10-Q · Quarter ended Sep 30, 2026

    Filed · 4 signals

    SEC EDGAR
  2. 10-Q · Quarter ended Mar 31, 2026

    Filed · 1 signal

    SEC EDGAR
    • International growthPositive

      Combined Europe, Asia and other markets net revenue increased 16% to $441.8 million

      Net revenue from Sleep and Breathing Health in combined Europe, Asia and other markets rose 16% to $441.8 million for the three months ended March 31, 2026.

      $441.8M

      Net revenue from combined Europe, Asia and other markets for the three months ended March 31, 2026

      16%

      revenue increase compared to prior year period

  3. 10-Q · Quarter ended Dec 31, 2025

    Filed · 1 signal

    SEC EDGAR
    • International growthPositive

      Combined Europe, Asia, and other markets revenue grew 12% to $420.9 million

      Net revenue in combined Europe, Asia and other markets increased 12% (6% on a constant currency basis) to $420.9 million for the three months ended December 31, 2025, driven by higher demand and unit sales for devices and masks.

      $420.9M

      combined Europe, Asia and other markets net revenue for the three months ended December 31, 2025

      12%

      increase in net revenue in combined Europe, Asia and other markets

Earnings calls

ResMed earnings headlines

From earnings call transcripts (Signal API type earnings-transcripts).

Earnings call headlines
Call dateWhat the company said
First-quarter revenue up 7% to $1.4B with gross margin expansionRevenue rose 7% on a core constant currency basis (6% reported) to $1.4 billion for Q1 FY2027. Non-GAAP gross margin expanded 50 basis points year-over-year to 62.5%, and non-GAAP EPS grew 14% to $2.91. Growth was supported by strong device and mask demand across the Americas and Rest of World.
Rest of World sleep device revenue up 13% via fleet refreshRest of World sleep device revenue grew 13% in Q1 FY2027, driven primarily by a fleet replacement cycle in France transitioning patients from AirSense 10 to AirSense 11. Rest of World mask revenue also increased 11%, while Americas sleep device revenue grew 6% and masks grew 10%.
Launches AirTouch F40 fabric mask and AirCurve 11 bilevelsThe company introduced its third fabric mask, the AirTouch F40 with ComfiSoft fabric cushion in the US, achieving a 91% initial comfort rating and a 6% adherence improvement over silicone equivalents. This follows the launch of AirCurve 11 ST and ST-A bilevel platforms for complex sleep apnea and overlap syndrome.
R&D up 14% funding AI sleep tools and device platformsNon-GAAP R&D expenditures grew 14% on a constant currency basis (16% reported), driven by investments in next-generation platforms and AI tools. Initiatives include GenAI digital sleep coach Dawn, which logged over 2.1 million inquiries, and FDA-cleared Smart Comfort, which demonstrated a 4.3% compliance increase.
Closed MatrixCare divestiture and integrating Nidra therapy acquisitionOn September 1, the divestiture of MatrixCare closed, sharpening focus on core Residential Care Software lines Brightree and MEDIFOX DAN, which grew 8%. The company is also integrating Nidra, an RLS therapy acquired via Noctrix, while pursuing sub-$500 million tuck-in acquisitions.
Reaches 13M app downloads and 28K inbound wearable usersDownloads of the myAir patient management application surpassed 13 million users. Additionally, integration with smart ring partner OURA drove approximately 28,000 app users to resmed.com by September 30, with 72% of assessed users identifying as previously undiagnosed for obstructive sleep apnea.

Signal API · MCP

Track ResMed with the Signal API

One POST /v1/companies/enrich call with resmed.com returns ResMed 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"resmed.com","signal_types":["sec-10q"],"limit":20}'

Bulk data

Need this signal for 10,000+ companies?

Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.

Talk to sales

Same industry

Questions about ResMed 10-Q

When did ResMed file its latest 10-Q?
ResMed filed its latest 10-Q (Quarter ended Sep 30, 2026) on Oct 29, 2026. The one before it was filed on Apr 30, 2026.
What did ResMed disclose in its latest 10-Q?
From the filing dated Oct 29, 2026: ResMed completed MatrixCare business sale on September 1, 2026, recognizing $62 million gain
What did ResMed say on its recent earnings calls?
Q1 FY2027: First-quarter revenue up 7% to $1.4B with gross margin expansion (dated Oct 29, 2026).
Where can I read ResMed's 10-Q filing?
The full filing is on SEC EDGAR: https://www.sec.gov/Archives/edgar/data/943819/000094381926000089/rmd-20260930.htm. This page summarizes what the filing says and links to it.

Page updated , the date of the newest row on this page.

Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.

Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.

Data as of .

How this data is built →Get it from the Signal API →